Literature DB >> 20563765

Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer.

Yongning Zhou1, Gaozhong Li, Jing Wu, Zhiyi Zhang, Zhengqi Wu, Ping Fan, Tianjun Hao, Xu Zhang, Min Li, Fuhua Zhang, Qiang Li, Bing Lu, Liang Qiao.   

Abstract

E-cadherin, vascular endothelial growth factor (VEGF), and matrix metalloproteinases (MMPs) are important molecules involved in tumor metastasis. In this study, we examined the expressions of E-cadherin, VEGF, MMP-1, MMP-2, and microvessel density (MVD), as well as microlymphatic vessel density (MLVD) in 200 cases of gastric cancer tissues, and determined the relationship between these parameters and the clinicopathological features and patient survival. Protein expressions, MVD, and MLVD were detected by immunohistochemistry. The correlation between the expression levels of these molecules and the clinicopathological features was analyzed. Patient survival was estimated by Kaplan and Meier analysis. Compared to normal gastric mucosa, expression of E-cadherin was reduced in 78% of gastric cancer tissues and 44.6% of adjacent non-cancerous gastric tissues. VEGF was positive in 81.5% of gastric cancer tissues, 35.7% of adjacent non-cancerous gastric tissues, and 10% of normal gastric mucosa. MMP-1 was positive in 80.5% of gastric cancer tissues, 69.6% of adjacent non-cancerous gastric tissues, and 20% of normal gastric mucosa. Reduced expression of E-cadherin was closely correlated with poor tumor differentiation and a deeper tumor invasion. Increased expressions of VEGF and MMP-1 were closely linked with poor differentiation and Lauren classification. Increased expression of MMP-2 was closely correlated with more lymph node metastasis, a deeper invasion, and a larger tumor size. More MVD was observed in VEGF-positive tissues than in VEGF negative tissues. Therefore, abnormal expressions of E-cadherin, VEGF, MMP-1, and MMP-2 are widely present in gastric cancer tissues. Abnormal expressions of E-cadherin, VEGF, and MMP-2 may represent the early molecular changes in the development of gastric cancer. Positive expression of E-cadherin and negative expression of VEGF and MMP-2 are correlated with a better patient survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20563765     DOI: 10.1007/s13277-010-0068-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  22 in total

Review 1.  Matrix metalloproteinases: they're not just for matrix anymore!

Authors:  L J McCawley; L M Matrisian
Journal:  Curr Opin Cell Biol       Date:  2001-10       Impact factor: 8.382

Review 2.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

Authors:  Daniel J Hicklin; Lee M Ellis
Journal:  J Clin Oncol       Date:  2004-12-07       Impact factor: 44.544

3.  Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma.

Authors:  Huachuan Zheng; Hiroyuki Takahashi; Yoshihiro Murai; Zhengguo Cui; Kazuhiro Nomoto; Hideki Niwa; Koichi Tsuneyama; Yasuo Takano
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

Review 4.  Inactivation of the E-cadherin-mediated cell adhesion system in human cancers.

Authors:  S Hirohashi
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

5.  Loss of XIAP sensitizes colon cancer cells to PPARgamma independent antitumor effects of troglitazone and 15-PGJ2.

Authors:  Liang Qiao; Yun Dai; Qing Gu; Kwok Wah Chan; Juan Ma; H Y Lan; Bing Zou; Christoph Rocken; Matthias P A Ebert; Benjamin C Y Wong
Journal:  Cancer Lett       Date:  2008-05-13       Impact factor: 8.679

Review 6.  The extracellular matrix protein 1: its molecular interaction and implication in tumor progression.

Authors:  S Sercu; L Zhang; J Merregaert
Journal:  Cancer Invest       Date:  2008-05       Impact factor: 2.176

7.  Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis.

Authors:  Frank Kuhnert; Betty Y Y Tam; Barbara Sennino; John T Gray; Jenny Yuan; Angeline Jocson; Nihar R Nayak; Richard C Mulligan; Donald M McDonald; Calvin J Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-16       Impact factor: 11.205

Review 8.  E-cadherin mediated adhesion system in cancer cells.

Authors:  H Shiozaki; H Oka; M Inoue; S Tamura; M Monden
Journal:  Cancer       Date:  1996-04-15       Impact factor: 6.860

9.  Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer.

Authors:  F J G M Kubben; C F M Sier; W van Duijn; G Griffioen; R Hanemaaijer; C J H van de Velde; J H J M van Krieken; C B H W Lamers; H W Verspaget
Journal:  Br J Cancer       Date:  2006-04-10       Impact factor: 7.640

10.  Blood flow influences vascular growth during tumour angiogenesis.

Authors:  R Nasu; H Kimura; K Akagi; T Murata; Y Tanaka
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  20 in total

1.  Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?

Authors:  Hilda Wong; Thomas Yau
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

2.  Interaction between cyclooxygenase-2, Snail, and E-cadherin in gastric cancer cells.

Authors:  Xiao-Jun Liu; Zhao-Feng Chen; Hai-Long Li; Ze-Nan Hu; Min Liu; Ai-Ping Tian; Da Zhao; Jing Wu; Yong-Ning Zhou; Liang Qiao
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

Review 3.  The prognostic role of matrix metalloproteinase 2 in gastric cancer: a systematic review with meta-analysis.

Authors:  Weisong Shen; Hongqing Xi; Bo Wei; Lin Chen
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-08       Impact factor: 4.553

4.  Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients.

Authors:  Futao Hou; Weijie Yuan; Jin Huang; Liyuan Qian; Zhikang Chen; Jie Ge; Shaobin Wu; Jinxiang Chen; Jixu Wang; Zihua Chen
Journal:  Med Oncol       Date:  2011-12-22       Impact factor: 3.064

Review 5.  Clinical management of advanced gastric cancer: the role of new molecular drugs.

Authors:  Ferdinando De Vita; Natale Di Martino; Alessio Fabozzi; Maria Maddalena Laterza; Jole Ventriglia; Beatrice Savastano; Angelica Petrillo; Valentina Gambardella; Vincenzo Sforza; Luigi Marano; Annamaria Auricchio; Gennaro Galizia; Fortunato Ciardiello; Michele Orditura
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

6.  Application of CT texture analysis in predicting histopathological characteristics of gastric cancers.

Authors:  Shunli Liu; Song Liu; Changfeng Ji; Huanhuan Zheng; Xia Pan; Yujuan Zhang; Wenxian Guan; Ling Chen; Yue Guan; Weifeng Li; Jian He; Yun Ge; Zhengyang Zhou
Journal:  Eur Radiol       Date:  2017-06-22       Impact factor: 5.315

7.  Immunoexpression of metalloproteinases 2 and 14 and TIMP-2 inhibitor in main types of primary gastric carcinomas and lymph node metastasis.

Authors:  Daniel Cordeiro Gurgel; José Telmo Valença-Junior; Conceição Aparecida Dornelas; Renato Braga Vieira; João Tarcisio Alves Maia-Filho; Roberto Cesar Pereira Lima-Junior; Ronaldo Albuquerque Ribeiro; Paulo Roberto Carvalho Almeida
Journal:  Pathol Oncol Res       Date:  2014-05-07       Impact factor: 3.201

Review 8.  Gastric cancer-molecular and clinical dimensions.

Authors:  Roopma Wadhwa; Shumei Song; Ju-Seog Lee; Yixin Yao; Qingyi Wei; Jaffer A Ajani
Journal:  Nat Rev Clin Oncol       Date:  2013-09-24       Impact factor: 66.675

9.  Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis.

Authors:  Chun-Yu Li; Peng Yuan; Shu-Sen Lin; Cheng-Fei Song; Wei-Yu Guan; Lu Yuan; Rong-Bin Lai; Ying Gao; Yan Wang
Journal:  Tumour Biol       Date:  2012-12-27

10.  mRNA Expression Analysis of E-Cadherin, VEGF, and MMPs in Gastric Cancer: a Pilot Study.

Authors:  Puneet Kumar; Arun Sebastian; Khushi Verma; Ruhi Dixit; Soni Kumari; Juhi Singh; Satyendra Kumar Tiwary; Gopeshwar Narayan
Journal:  Indian J Surg Oncol       Date:  2020-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.